Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Atriopeptin III** is a 24-amino acid peptide fragment (ANP 127-150) of rat atrial natriuretic peptide, functioning as a potent vasodilator, natriuretic, and diuretic agent[1][4][7]. Its primary mechanism is binding to natriuretic peptide receptors to induce vasodilation, promote sodium and water excretion, lower blood pressure, and increase glomerular filtration rate[1][3][5]. AP III demonstrates protective properties against ischemic acute renal failure and enhances cardiac relaxation by a mechanism involving endocardial endothelium[3][6][9]. Mostly characterized in animal models, it has been investigated for potential use in treating volume overload—including chronic renal failure, congestive heart failure, and possibly as a renal protective agent[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atriopeptin III.